The stock of Alaunos Therapeutics Inc. (NASDAQ:TCRT) increased by $0.03 on Tuesday to finish at $0.15, up 23.22 percent. The last five days have seen an average of 2,770,840 shares of common stock traded. 5 times new highs were reached in the current year, with a fall of -$0.4989. The average number of shares traded over the last 20 days was 1,803,170, while the average volume over the last 50 days totaled 2,405,850.
TCRT stock appreciated 21.72% since last month. On 09/15/23, the company’s shares reached a one-month low of $0.1111. The stock touched a high of $2.80 on 01/17/23, after rallying from a low of $0.11 in 52 weeks. The price of TCRT stock has declined by -76.86% or -$0.4989 this year, reaching a new high 5 times. Still, the stock price is down -94.64% from the 52-week high.
Insider Transactions
TCRT stock investors should be aware that Alaunos Therapeutics Inc. (TCRT) stock had its last reported insider trading activity 19 days ago on Sep 01. On Sep 01, Chief Executive Officer Boyle Kevin S. Sr. sold 68,014 shares at $0.14 each. This transaction resulted in the insider making $9,542. On Nov 29, Vieser Jaime added 1,250,000 shares at a price of US$0.65. After the transaction, the insider now owns 1,250,000 shares. Director Postma Robert W had earlier bought 750,000 shares on Nov 29 for $0.65 a share. The transaction was completed for $487,500.
Valuation Metrics
Beta for the stock is 0.27. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 12.58, the price-to-book (PB) ratio of 1.67.
Financial Health
For the three months ended June 29, Alaunos Therapeutics Inc.’s quick ratio was 3.70, while its current ratio was 3.70, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $38.03 million and revenue of $2.92 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. TCRT’s return on assets (ROA) during the last 12 months has been -70.50%. There was a -63.40% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -120.90%.
Earnings Surprise
According to Alaunos Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. It was predicted that Alaunos Therapeutics Inc.’s quarterly earnings would be -$0.04, but it ended up being -$0.04. EBITDA was -$6.42 million for the quarter. At the end of Alaunos Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 6.28 million, while its total debt was $1.56 million. Equity owned by shareholders amounts to $240.63 million.
Technical Picture
Here’s a quick look at Alaunos Therapeutics Inc.’s (TCRT) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 51.81%, suggesting the stock is Neutral, with a 114.77% historical volatility rate.
The stochastic %K and %D were 52.20% and 33.96% respectively, while the average true range (ATR) was 0.0191. Based on the 14-day stochastic reading of 89.07%, the RSI (14) reading is 40.14%. On the 9-day MACD Oscillator, the stock is at 0.0045.
Analyst Ratings
Analysts have assigned Alaunos Therapeutics Inc. (TCRT) an Hold rating. TCRT is a stock that is recommended for selling by 0 brokerage firms, while 2 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 0 others recommend it as a buy.
What is TCRT’s price target for the next 12 months?
The current consensus forecast for the stock is between $7.50 and $7.50, with a median target price of $7.50. In analyzing these forecasts, the average price target given by analysts for Alaunos Therapeutics Inc. (TCRT) is $7.50.
